Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial

Guilhot, Francois; Rigal-Huguet, Françoise; Guilhot, Joëlle; Guerci-Bresler, Agnès-Paule; Maloisel, Frédéric; Rea, Delphine; Coiteux, Valérie; Gardembas, Martine; Berthou, Christian; Vekhoff, Anne; Jourdan, Eric; Berger, Marc; Fouillard, Loïc; Alexis, Magda; Legros, Laurence; Rousselot, Philippe; Delmer, Alain; Lenain, Pascal; Escoffre Barbe, Martine; Gyan, Emmanuel; Bulabois, Claude-Eric; Dubruille, Viviane; Joly, Bertrand; Pollet, Bertrand; Cony-Makhoul, Pascale; Johnson-Ansah, Hyacinthe; Mercier, Melanie; Caillot, Denis; Charbonnier, Aude; Kiladjian, Jean-Jacques; Chapiro, Jacques; Penot, Amélie; Dorvaux, Véronique; Vaida, Iona; Santagostino, Alberto; Roy, Lydia; Zerazhi, Hacene; Deconinck, Eric; Maisonneuve, Herve; Plantier, Isabelle; Lebon, Delphine; Arkam, Yazid; Cambier, Nathalie; Ghomari, Kamel; Miclea, Jean-Michel; Glaisner, Sylvie; Cayuela, Jean-Michel; Chomel, Jean-Claude; Muller, Marc; Lhermitte, Ludovic

doi:10.1038/s41375-020-01117-w

Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial

The STI571 prospective randomised trial (SPIRIT) French trial is a four-arm study comparing imatinib (IM) 400 mg versus IM 600 mg, IM 400 mg + cytarabine (AraC), and IM 400 mg + pegylated interferon alpha2a (PegIFN-α2a) for the front-line treatment of chronic-phase chronic myeloid leukaemia (CML)…